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Purpose: The objective of this report is describe the
results of 2 studies that examined the pharmacoki-
netic parameters, safety proﬁle, and tolerability of
single and multiple ascending doses of oral delaﬂox-
acin and the effects of food, sex, and age on oral
delaﬂoxacin pharmacokinetic parameters, safety pro-
ﬁle, and tolerability.
Methods: The ﬁrst study contained 3 parts and
used unformulated delaﬂoxacin in a capsule. Part 1
was a randomized, double-blind, placebo-controlled,
single (50, 100, 200, 400, 800, 1200, and 1600 mg)
ascending-dose study of oral delaﬂoxacin in healthy
men. Part 2 was a single-dose crossover study in
which 20 men received 250 mg delaﬂoxacin with or
without food. Part 2 also included a parallel group,
double-blind, placebo-controlled study in 16 women
and 16 elderly men and women who were randomized
(3:1) to receive 250 mg delaﬂoxacin or placebo. Part 3
was a randomized, double-blind, placebo-controlled,
multiple (100, 200, 400, 800, 1200 mg once daily for
5 days) ascending-dose study of oral delaﬂoxacin in
healthy men. The second study was a single-dose,
randomized, 3-period crossover study in which par-
ticipants received 900 mg delaﬂoxacin (2  450-mg
tablets) under fasted conditions, with a high-fat meal,
or fasted with a high-fat meal 2 hours after dosing.
Serial blood samples were collected, and plasma
pharmacokinetic parameters of delaﬂoxacin were
determined.
Findings: Delaﬂoxacin Cmax and AUC0–1 increased
with increasing oral dose over the dose range of 50 to
1600 mg. The increases in delaﬂoxacin AUC0–1 were
dose proportional at doses of Z200 mg. Steady state
was reached by day 3 of dosing with minimal accu-
mulation of delaﬂoxacin. The Cmax of delaﬂoxacin was
decreased slightly in the presence of food. No sex
difference in delaﬂoxacin pharmacokinetic parametersJanuary 2016was observed. In the elderly men and women, mean
delaﬂoxacin Cmax and AUC0–1 were 35% higher than
observed for young adults, which could be partially
explained by a decrease in the creatinine clearance in the
elderly men and women. Delaﬂoxacin was well tolerated
at the tested doses, with gastrointestinal adverse effects
observed more commonly at doses Z1200 mg.
Implications: Delaﬂoxacin exhibits linear pharma-
cokinetic parameters that reached steady state after 3
days of daily oral dosing with minimal accumulation.
Delaﬂoxacin was well tolerated throughout both
studies, with gastrointestinal effects observed at the
higher doses (Z1200 mg). (Clin Ther. 2016;38:39–
52) & 2016 The Authors. Published by Elsevier HS
Journals, Inc.
Key words: delaﬂoxacin, food, elderly, pharmaco-
kinetics, sex, tolerability.INTRODUCTION
Delaﬂoxacin (RX-3341, ABT-492, WQ-3034) is an
investigational ﬂuoroquinolone antibiotic with a
broad spectrum of activity against gram-positive patho-
gens (methicillin-susceptible Staphylococcus aureus,
methicillin-resistant strains of S aureus, Streptococcus
pyogenes, and Streptococcus enterococci), gram-nega-
tive pathogens (Escherichia coli, Klebsiella species,
and Pseudomonas aeruginosa), and anaerobes.1–3 The
bactericidal action of delaﬂoxacin results from dual
inhibition of topoisomerase II (DNA gyrase) and top-
oisomerase IV, which are required for bacterial DNA39
Clinical Therapeuticsreplication, transcription, repair, and recombination.4,5
Delaﬂoxacin has an anionic structure, which may be a
potential advantage over other ﬂuoroquinolones in that
its antibactericidal potency is increased under acidic
conditions.6,7 This could be a beneﬁt in the treatment
of infections such as S aureus, which can survive in
mildly acidic environments.7 In a randomized Phase II
trial comparing 2 doses of intravenous delaﬂoxacin
with tigecycline in patients with various complicated
skin and skin-structure infections, IV delaﬂoxacin given
at 300 mg or 450 mg every 12 hours produced clinical
cure rates comparable to tigecycline.8 In a separate Phase
II study, in patients with acute bacterial skin and skin
structure infections (ABSSSIs), cure rates were similar
between delaﬂoxacin and linezolid but statistically
greater with delaﬂoxacin versus vancomycin.9 In these
2 Phase II studies, delaﬂoxacin was well tolerated, with
the most frequent adverse events (AEs) reported being
nausea, vomiting, and diarrhea. Currently, delaﬂoxacin
is in Phase III trials being developed both as an
intravenous and oral treatment of ABSSSIs.10
The present report describes the results of 2 studies
conducted to evaluate the safety proﬁle, tolerability,
and pharmacokinetic parameters of oral doses of
delaﬂoxacin. The ﬁrst study was a single and multiple
ascending-dose study that included evaluations of the
effects of food, sex, and age. In this ﬁrst study,
delaﬂoxacin was administered as an unformulated
chemical in a gelatin capsule. The second study was
a food-effect study. The second study used delaﬂox-
acin in a formulated tablet, which is the same tablet
formulation currently being used in a Phase III study
on the treatment of ABSSSI with intravenous and oral
delaﬂoxacin.PATIENTS AND METHODS
Both studies were conducted according to good
clinical practice and followed the ethical principles
of the Declaration of Helsinki. An independent ethics
committee (Integreview, Austin, TX, and Guy’s Re-
search Ethics Committee, London, United Kingdom)
approved the study protocols and all amendments.
Written informed consent was signed by all the
participants.Study Participants
Study participants were healthy based on medical
history, physical examination, clinical laboratory40evaluations, and 12-lead ECG. Participants were able
to comply with the protocol and had a body mass
index 418 through 28 kg/m2 (18–30 kg/m2 for the
food-effect study). In the 3-part dose-escalation study,
participants were men and women 18 through 40
years of age; elderly individuals were Z65 years of
age. In the food-effect study, men and women 18
through 55 years were included. Women were post-
menopausal, surgically sterile, or used adequate con-
traception. Participants were nonsmokers and willing
to abstain from alcohol, caffeine, grapefruit, or grape-
fruit juice (ascending-dose study) and methylxanthine-
containing beverages or food (food-effect study).
The following individuals were excluded: those
who had history of adverse reactions to quinolone
antibiotics; those with evidence of clinically signiﬁcant
disease; those undergoing any surgical procedure that
would interfere with gastric motility, pH, or absorp-
tion; those with gastric upset 1 week before the study
start; those with a positive drug or alcohol screen
result; users of prescription or over-the-counter med-
ications; those with positive hepatitis A IgM, hepatitis
B antigen, hepatitis C antibody, or HIV test results; or
users of known inhibitors or inducers of drug metab-
olism 1 month before the start of the study. Individ-
uals who used 42 g/d of acetaminophen were
excluded from the food-effect study.
Single and Multiple Ascending-Dose Study
(Unformulated Drug in Capsule)
This was a Phase 1, single-center study that con-
sisted of 3 parts. Part 1 was a randomized, parallel-
group, placebo-controlled study to evaluate the safety
proﬁle, tolerability, and pharmacokinetic parameters
of single ascending oral doses of delaﬂoxacin in
healthy mean (aged 18–40 years). Fifty-six men were
assigned 1 of 7 dose groups (50, 100, 200, 400, 800,
1200, and 1600 mg). In each dose group, 8 men were
randomly assigned in a 3:1 ratio to receive a single
oral dose of delaﬂoxacin (n ¼ 6) or placebo (n ¼ 2).
The dosing schedule was such that successively higher
doses of delaﬂoxacin were given after the safety proﬁle
of the preceding dose was determined. Delaﬂoxacin
was administered in the morning after an overnight
fast of at least 8 hours.
Part 2 was designed to determine the effect of food
on the bioavailability of delaﬂoxacin and to assess the
safety proﬁle, tolerability, and pharmacokinetic pa-
rameters of delaﬂoxacin in women and healthy elderlyVolume 38 Number 1
R. Hoover et al.people. The food-effect study was a randomized,
single-dose, double-blind, 2-period crossover study.
A total of 20 healthy men received delaﬂoxacin (250
mg) or placebo in a 4:1 ratio and were fed (stand-
ardized high-fat breakfast 30 minutes before dosing)
in one period and fasted (overnight for at least 8
hours) in the other period. A washout of 14 days
separated the 2 periods. The study in healthy women
(18–40 years of age) and elderly people (Z65 years of
age) was a randomized, single-dose, parallel-group,
double-blind, placebo-control study. Half of the eld-
erly participants were female and half were male.
A total of 16 women and 16 elderly women were
randomized 3:1 to receive a single dose of delaﬂoxacin
(250 mg) or placebo under fasting conditions.
Part 3 of the study was a multiple ascending-dose
trial of delaﬂoxacin (100, 200, 400, 800, and
1200 mg) or placebo administered once daily for 5
days to fasting, healthy men (18–40 years of age).
Sixty individuals were assigned to parallel groups of
12 people each. In each dose group, participants were
randomly assigned 2:1 to delaﬂoxacin or placebo. The
dosing schedule was designed such that successively
higher doses were administered after the safety of the
preceding dose had been determined. Participants in
parts 1 and 2 were conﬁned to the study unit for the
day before dosing through 48 hours after dosing.
Participants in part 3 were conﬁned to the study unit
for 7 days, from the day before dosing to 48 hours
after the last dose.
Food-Effect Study (Tablet Formulation)
This food-effect study was a Phase I, single-dose,
randomized, open-label, 3-period, 6-sequence cross-
over study in 30 healthy men and women. Participants
were randomly assigned to 1 of 6 treatment sequences
in which a single 900-mg (2  450-mg formulated
tablet) oral dose of delaﬂoxacin was given under the
following 3 conditions: (1) after an overnight fast of at
least 10 hours, (2) after an overnight 10-hour fast
followed by a standardized high-fat breakfast 30
minutes before dosing, and (3) an overnight 10-hour
fast followed by a high-fat meal 2 hours after dosing.
The study consisted of a screening period, 3 treatment
periods, and end-of-study or early termination period.
There was at least a 7-day washout between each
treatment period.
The standardized high-fat breakfast for both food-
effect studies consisted of 2 eggs fried in butter, 2January 2016strips of bacon, 2 slices of toast with butter, 4 oz of
hash brown potatoes, and 8 oz of whole milk.
Blood and Urine Sample Collection
For parts 1 and 2 (single dose) of the 3-part
ascending-dose study, blood samples (10 mL) were
collected before dosing and at 0.25, 0.5, 1, 1.5, 2,
2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 16, 20, 24, 30, 36,
and 48 hours after dosing. For part 3 (multiple dose),
blood samples were collected before dosing each day
from days 1 through 5 of dosing. Blood samples were
also collected at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 18, and
24 hours after dosing on days 1 and 5. Two addi-
tional blood samples were collected at 36 and 48
hours after the day 5 dose. Plasma was prepared
from blood by centrifugation. For part 1 of the
ascending-dose study, urine samples were collected
before dosing up to 1 hour before dosing and from 0
to 2, 2 to 4, 4 to 8, 8 to 12, 12 to 24, and 24 to 48
hours after dosing. For part 3, urine samples were
collected before dosing (up to 1 hour before dosing
on day 1) and during the interval of 0 to 24 hours
after the last dose on day 5.
For the food-effect study, blood samples (10 mL)
were collected before dosing and at 0.15, 0.5, 0.75, 1,
1.25, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 16, 20, 24, 36, and
48 hours after each treatment. Plasma and urine sam-
ples were analyzed for delaﬂoxacin concentrations.
Bioanalytical Methods
Plasma and urine samples were kept frozen at
201C or colder. Samples from the 3-part asc-
ending-dose study were analyzed for delaﬂoxacin
concentration using an LC-MS/MS method with a
concentration range of 8.0 to 5366.3 ng/mL. Plasma
and urine samples were acidiﬁed, spiked with internal
standard, and extracted by partitioning with hexane:
ethyl acetate (1:3, v/v). The extract was subjected to
HPLC analysis using a Waters XTerra RP18 column,
with a mobile phase consisting of acetonitrile:aqueous
0.1% formic acid (2:3, v/v). Quantitation was accom-
plished by triple quadrupole mass spectrometry and
monitoring the precursor-to-product ion pairs m/z
441-379 for delaﬂoxacin and m/z 421-359 for
the internal standard. The mean accuracy ranged from
93.8% to 111.8%, and the precision of the assay
ranged from 7.6% to 15.7%.
Plasma samples from the food-effect study with the
tablet formulation were analyzed using a LC-MS/MS41
Clinical Therapeuticsmethod with an assay range of 5.00 to 5000 ng/mL.
Samples were extracted with hexane:ethyl acetate
using supported liquid extraction and analyzed by
LC-MS/MS. Quantitation was accomplished by triple
quadrupole mass spectrometry and monitoring the
precursor-to-product ion pairs m/z 441-379 for
delaﬂoxacin and m/z 446-381 for the internal stand-
ard. The mean accuracy was within 85% to 115% of
the theoretical accuracy, and the precision of the assay
did not exceed 15%.
Pharmacokinetic Analysis
Pharmacokinetic parameters were calculated by
noncompartmental methods using WinNonlin Version
6.2.1 software (Pharsight Corp, Mountain View, CA).
The Tmax and Cmax were the observed values. The ke
was determined from the slope of a least-squared
linear regression of the log of the plasma concentra-
tions from the terminal log-linear phase. The AUC-
time curve from time zero to the time of the last
measurable concentration or until 24 hours after
dosing (AUC0–t or AUC0–24) was calculated by the
linear trapezoidal method. The AUC was extrapolated
to inﬁnite time (AUCext) by dividing the last meas-
urable plasma concentration (Ct) by ke. The AUC0–1
was calculated as follows: AUC1 ¼ AUC0–t þ
AUCext. The CL/F was calculated by dividing the
administered dose by the AUC0–1 (single dose) or
AUC0–24 (after 5 days of dosing). The apparent
volume of distribution in the terminal phase was
calculated as CL/F C ke. The accumulation ratio
was the ratio of day 5 AUC0–24 to the day 1 AUC0–24.
The fraction of dose recovered as unchanged delaﬂox-
acin in urine was calculated as the total amount of
delaﬂoxacin recovered in urine (Au) for the 48-hour
interval after single dose or the 24-hour interval on day
5 divided by the total administered dose. Renal
clearance was Au/AUC0–48 after single dose or
Au/0–AUC24 after multiple dose. Creatinine clearance
was calculated according to method of Cockcroft and
Gault.11
Statistical Analysis
For the single and multiple ascending-dose study,
statistical analysis was performed for log Cmax, log
Cmin (day 5 only), log AUC, and log ke. For dose-
proportionality assessments, Cmax, AUC, and Cmin
were dose normalized before log transformation. An
ANCOVA with weight as a covariate was used for42testing the hypothesis of invariance of each pharma-
cokinetic variable with dose. The primary test was
performed on a linear contrast in the dose-level effects,
with the contrast chosen so that the test had good
power for a trend with dose assuming a linear
relationship between dose and response.
The effect of food was analyzed using an ANOVA
for log-transformed Cmax and AUC and for Tmax. The
ANOVA model included effects for sequence, subject
nested within sequence, period, and dosing condition
(fasting or fed). Two 1-sided test procedures were
performed via a 90% CI method. The 90% CI for
relative bioavailability was computed by exponentiat-
ing the end points of the CI for the difference of
logarithm means.12 A point estimate of relative
bioavailability was obtained.
To assess the sex and age effects, 2 analyses were
performed on log Cmax, log AUC, Tmax, and ke. In the
ﬁrst analysis, a 2-way ANOVA model was used on
data from younger men and women under fasting
conditions. The model included the effects for sex,
period, and their interaction. In the second analysis, a
2-way ANOVA model was used with classiﬁcation by
sex and age (young or elderly) and with interaction
included on the data for all doses administered under
fasting conditions. All tests for the 3-part study were
performed at the 0.05 level, using the GLM and
MIXED procedures of SAS/STAT software, version
6.12.13
For the food-effect study with the tablet formula-
tion, to assess the effect of food in the fed states (test)
to the fasted state (reference), a linear mixed-effect
model was performed on the natural log-transformed
values of AUC0–t, AUC0–1, and Cmax with sequence,
treatment, and period as ﬁxed effects and subject
nested within sequence as a random effect. The geo-
metric least-squares (LS) mean ratios of the 2 test
treatments to the reference treatment for AUC0–t,
AUC0–1, and Cmax were calculated by the antilog of
the LS mean difference of the natural log-transformed
values. A 90% CI for each ratio was constructed as
the antilog of the 90% CI of the LS mean difference.
No adjustment was made for multiplicity. In addition,
the geometric LS means and corresponding 90% CIs
were computed for AUC0–t, AUC0–1, and Cmax by
taking the antilog of the LS means and corresponding
90% CIs from the linear mixed-effect model on the
natural logarithm of the corresponding pharmacoki-
netic parameters.Volume 38 Number 1
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The safety proﬁle was monitored at screening,
baseline, and throughout the study by physical
examinations, vital signs (systolic and diastolic blood
pressure, pulse rate, respiratory rate, temperature),
12-lead ECGs, laboratory evaluations (serum chem-
ical analysis; hematologic testing, including coagu-
lation parameters; urinalysis), and the assessment
of AEs.
For the single ascending-dose study parts 1 and 2,
AEs and vital signs were monitored daily for
3 days after dosing and laboratory evaluations were
monitored daily for 4 days after dosing. For the
multiple ascending-dose study, AEs, vital signs,
and concomitant medications were monitored
daily for days 1 through 7, and laboratory evaluations
were performed on days 1, 3, 5, and 7. Assessments of
AEs, vital signs, concomitant medications, and
laboratory evaluations were also made during the
outpatient visit, which occurred on days 9 through
12 of the study. The 12-lead ECG was performed at
baseline and 2, 4, 8, 24, and 48 hours after dosing for
the single ascending-dose study and on days 1, 5, and
7 and at the outpatient visit on days 9 through 12 for
the multiple ascending-dose study.
For the food-effect study, vital signs and clinical
laboratory evaluations occurred before dosing and at
the end of the study. A 12-lead ECG was taken before
dosing and at 2 and 48 hours after each dose. AEs
were monitored throughout the study.RESULTS
Demographic Characteristics and Disposition of
Study Participants
For the 3-part ascending-dose study, the demo-
graphic characteristics of the study participants
are summarized in Table I. A total of 152 adults
(136 men and 16 women) and 16 elderly individuals
(8 men and 8 women) were enrolled. All participants
completed parts 1 (single ascending dose) and 2
(effect of food, sex, and age) of the study; 3
participants in the 1200-mg dose group prematurely
discontinued part 3 (multiple ascending dose)
of the study because of an AE of diarrhea of
moderate intensity. A total of 30 participants were
enrolled in the second food-effect study with the
formulated tablet. All participants completed
the study.January 2016Pharmacokinetic Parameters
Single and Multiple Ascending Dose
The mean plasma concentration–time proﬁles after a
single dose are shown in Figure 1. The mean (SD)
pharmacokinetic parameters are listed in Table II.
Delaﬂoxacin was rapidly absorbed with a mean Tmax of
1 to 2.5 hours across dose groups. The plasma
concentration proﬁles decreased monoexponentially for
dosesr100 mg and biexponentially for dosesZ200 mg.
The mean half-life at the lower doses (50 and 100 mg)
wasr2.5 hours compared with 5.9 to 7.7 hours at doses
Z200 mg. Secondary peak plasma concentrations were
observed in several individuals (data not given). The
delaﬂoxacin Cmax from the 50-mg to 1600-mg doses in-
creased from 0.949 to 16.6 mg/mL, and the corresponding
AUC0–1 values increased from 1.82 to 81.7 h  mg/mL,
respectively. There was a signiﬁcant trend for the dose-
normalized Cmax to decrease with increasing dose
(P ¼ 0.0005). The AUC values were proportional to
dose at doses Z200 mg. Delaﬂoxacin was excreted
unchanged in the urine with the fraction of the dose
recovered in urine tending to decrease with increasing
dose (35.6% at 50 mg to 12.8% at 1600 mg).
The mean plasma concentration–time proﬁles of
delaﬂoxacin after multiple dosing are shown in
Figure 2. The mean (SD) pharmacokinetic parameters
are listed in Table III. After repeated dosing for 5 days,
the peak plasma delaﬂoxacin concentrations occurred
between 0.5 and 4.0 hours. As observed after a single
dose, with multiple dosing the dose-normalized Cmax
also tended to decrease with increasing doses (P ¼
0.0017). Cmin values increased from 0.105 to 1.79 mg/mL
in the dose range of 100 to 1200 mg/day, with no
signiﬁcant trend for dose-normalized Cmin to change
with dose (P ¼ 0.7936). There was a signiﬁcant trend
for dose-normalized AUC to decrease with increasing
dose, but the magnitude was not compelling (P ¼
0.0076). The AUC values were statistically higher on
day 5 compared with AUC values on day 1 (P ¼
0.0056), but the mean accumulation ratio was no more
than 1.24, indicating the accumulation was minimal
with once-daily dosing. Visual inspection of trough
delaﬂoxacin concentrations indicated that a steady state
was achieved after approximately 3 days of dosing
(Figure 2). Mean trough concentrations on days 3 and 4
were not statistically different from those on day 5
(PZ 0.1527). The harmonic mean elimination half-life,
which ranged from 4.2 to 8.5 hours, appeared to
lengthen with increasing dose, but statistical analysis43
Table I. Demographic characteristics of the study participants.
Demographic
Characteristic
Single and Multiple Ascending-Dose (Effects of Food, Sex, and Age) Study
Food-Effect Study
Formulated Tablet
(n ¼ 30)
Single Dose
(n ¼ 56)
Multiple Dose
(n ¼ 60)
Elderly
(n ¼ 16)
Young Woman
(n ¼ 16)
Food Effect
Unformulated
Drug (n ¼ 20)
Age, mean (SD)
[range], y
25.2 (5.53) [19–40] 25.7 (4.48) [19–39] 72.9 (5.6) [65–84] 24.4 (5.2) [18–39] 23.3 (5.2) [18–37] 33.7 (10.19) [22–55]
Weight, mean
(SD) [range], kg
75.6 (9.45) [60–90] 76.7 (7.83) [61–99] 70.7 (11.5) [71–90] 65.3 (7.6) [55–76] 73.8 (9.7) [59–88] 69.0 (12.15) [51.0–93.4]
Sex, No. (%)
Male 56 (100) 60 (100) 8 (50) 0 20 (100) 11 (36.7)
Female 0 0 8 (50) 16 (100) 0 19 (63.3)
Race, No. (%)
White 52 (92.9) 56 (93.3) 16 (100) 16 (100) 18 (90) 24 (80.0)
Black 1 (1.79) 3 (5.0) 0 0 2 (10) 6 (20.0)
Asian 2 (3.57) 0 (0.0) 0 0 0 0
Other 1 (1.79) 1 (1.67) 0 0 0 0
C
lin
ical
T
h
erap
eu
tics
4
4
V
o
lu
m
e
3
8
N
u
m
b
er
1
20
18
16
14
12
10
8
6
4
2
0
0 4 8 12 16 20 24
50 mg
100 mg
200 mg
400 mg
800 mg
1200 mg
1600 mg
50 mg
100 mg
200 mg
400 mg
800 mg
1200 mg
1600 mg
Pl
as
m
a 
D
el
af
lo
xa
ci
n 
(μ
g/
m
L)
Pl
as
m
a 
D
el
af
lo
xa
ci
n 
(μ
g/
m
L)
Time (h)
100
10
1
0.1
0.01
0.001
0 4 8  12
Time (h)
2016 24
Figure 1. Mean plasma delafloxacin concentration-time profiles after a single oral dose of 50, 100, 200, 400,
800, 1200, and 1600 mg. Top, linear scale; bottom, semilogarithmic scale.
R. Hoover et al.indicated no signiﬁcant trend for ke to change with dose
(P ¼ 0.01812). There was a time dependence in
delaﬂoxacin pharmacokinetic parameters because the
mean half-lives tended to increase from day 1 to Day 5.
Statistical analysis indicated that the elimination rate
constants were lower on day 5 than on day 1 (P ¼
0.0001). Because the calculation of volume of distribu-
tion is dependent on ke, Vz was larger on day 5
compared with day 5.
Effect of Age and Sex
The pharmacokinetic parameters for young and
elderly men and women are given in Table IV. ThereJanuary 2016was no effect of age on Tmax and ke between young and
elderly participants (P Z 0.0659). The mean values for
delaﬂoxacin Cmax and AUC0–1 were statistically
signiﬁcantly higher in elderly participants compared
with younger adults (P r 0.001). Because delaﬂoxacin
is cleared partially as unchanged drug in urine, an
evaluation of Cmax and AUC0–1 values versus
creatinine clearance was conducted. Plots of Cmax and
AUC0–1 values versus creatinine clearance reveal a trend
for these exposure parameters to increase with decreasing
creatinine clearance (Figure 3). The coefﬁcients of
determination (R2) for Cmax and AUC0–1 were 0.38
and 0.46, respectively.45
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46The pharmacokinetic parameters of delaﬂoxacin
were comparable between men and women for both
the young and elderly populations. Delaﬂoxacin pla-
sma concentrations were slightly higher in women
than men, but the effects of sex and sex by elderly
interaction were not signiﬁcant for any of the phar-
macokinetic parameters (P Z 0.5674).
Effect of Food (Unformulated Drug in Capsule)
When delaﬂoxacin (250 mg as unformulated chem-
ical in a gelatin capsule) was administered with a high-
fat meal compared with fasting conditions, the median
Tmax was delayed by 1.5 to 3 hours (P ¼ 0.0056), the
mean (SD) Cmax was reduced by 50% from 3.58
(0.602) mg/mL to 1.86 (0.635) mg/mL, and the mean
(SD) AUC was decreased by 15% from 13.6 (2.85)
h  mg/mL to 11.4 (1.96) h  mg/mL.
Effect of Food (Formulated Tablet)
The pharmacokinetic parameters for delaﬂoxacin
(900 mg as 2  450-mg formulated tablets) given
under fasting or fed conditions are given in Table V.
Statistical analysis is presented in Table VI. When
delaﬂoxacin was given with a high-fat meal, Cmax was
reduced by 20.5% compared with fasting conditions.
Total exposure (AUC0–t and AUC0–1) was not
affected by administration under fed conditions.
Safety Profile
The incidence of treatment-emergent AEs (TEAEs) was
highest in the 1200-mg (5 of 6 participants [83%]) and
1600-mg (3 of 6 participants [50%]) groups for the single
ascending dose and in the 800-mg (4 of 8 participants
[50%]) and 1200-mg (7 of 8 participant [88%]) groups
for the multiple ascending-dose portion of the study.
Diarrhea was the most comment TEAE reported, occur-
ring in 3 of 6 participants at 1200 mg and 2 of 6
participants at 1600 mg in part 1 (single dose); 3 of 16
men, 2 of 12 women, and 2 of 12 elderly participants
given 250 mg in part 2; and 1 of 8 participants at
100 mg, 5 of 8 participants at 200 mg, 1 of 8 participants
at 400 mg, 4 of 8 participants at 800 mg, and 4 of 8
participants at 1200 mg in part 3 (multiple dose). The 3
participants at the 1200-mg once-daily dose had diarrhea
of moderate intensity. All other incidents of diarrhea were
of mild intensity. Rash was observed sporadically in the
single (1 of 6 participants at 100 mg) and multiple (1 of 8
participants at 100 mg, 2 of 8 participants at 200 mg,
and 3 of 8 participants at 1200 mg) ascending-doseVolume 38 Number 1
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Figure 2. Mean plasma delafloxacin concentration-time profiles on day 1 (upper left) and day 5 (upper right).
Mean plasma delafloxacin trough concentrations on days 1 through 6 (lower left) after
administration of delafloxacin once a day at doses of 100, 200, 400, 800, and 1200 mg.
R. Hoover et al.portions of the study but without a clear dose-response
relationship. No important differences in the frequency or
character of TEAEs were observed based on age, sex, or
feeding status relative to the ascending dose portions of
the study. Changes in laboratory ﬁndings and vital signs
were minor and not considered clinically signiﬁcant. In
the multiple ascending-dose portion of the study, 7 of 40
delaﬂoxacin-treated participants had values above the
normal range for alanine aminotransferase (ALT), includ-
ing 1 participants with an abnormal ALT value at
baseline. Elevated values of ALT were observed after
day 5, the end of dosing and conﬁnement, and on days 7
(4 participants) and 9 (2 participants). One participant
had elevated ALT values ﬁrst observed on the last day of
dosing. Two participants had elevated ALT values 42
times the upper limit of normal, but no participant hadJanuary 2016elevations 43 times the upper limit of normal. No clear
dose response was observed for participants with elevated
ALT values, and most elevated ALT values tended to
occur on day 9, which was 4 days after the end of dosing
and conﬁnement; therefore, the association of these
elevations to study drug cannot be clearly established.
No concomitant elevations of alkaline phosphatase were
observed. Both the Bazett and Fridericia correction
methods were used for QTc evaluation. No evidence of
signiﬁcant QTc interval prolongation with delaﬂoxacin
treatment was observed. Overall, delaﬂoxacin was well
tolerated at the single and multiple doses administered.
Food, sex, and age did not appear to signiﬁcantly affect
the safety proﬁle.
In the food-effect study with tablet formulation,
TEAEs were reported by 7 participants (25.9%)47
Table III. Pharmacokinetic parameters after multiple daily doses of oral delafloxacin (neat chemical in gelatin
capsule).
Pharmacokinetic Parameter
Delaﬂoxacin Once Daily, mg
100 (n ¼ 8) 200 (n ¼ 8) 400 (n ¼ 8) 800 (n ¼ 8) 1200 (n ¼ 5)
Day 1
Tmax, median (range), h 1.0 (0.5–3.0) 0.8 (0.5–2.0) 1.0 (0.5–2.0) 1.0 (0.5–2.0) 1.0 (0.5–3.0)
Cmax, mean (SD), mg/mL 1.36 (0.452) 3.17 (0.699) 4.49 (0.965) 8.18 (2.36) 11.5 (2.96)
Cmax per dose, mg/mL/mg 0.0136 0.0159 0.0112 0.0102 0.0096
AUC0–1, mean (SD), (h  mg/mL) 4.06 (0.576) 11.2 (1.26) 14.8 (2.13) 28.0 (8.13) 50.6 (8.92)
AUC0–1 per dose, (h  mg/mL/mg) 0.041 0.056 0.037 0.035 0.042
t½, harmonic mean, h 3.2 3.8 4.1 4.3 4.5
CL/F, mean (SD), L/h 25.1 (3.7) 18.0 (2.0) 27.5 (4.0) 30.5 (7.9) 24.4 (4.4)
Vz/F, mean (SD), L 121.1 (32.2) 110.2 (39.8) 210.4 (139.6) 211.1 (89.1) 171.8 (77.4)
Day 5
Tmax, median (range), h 0.8 (0.5–2.0) 1.0 (0.5–4.0) 1.0 (1.0–2.0) 1.0 (0.5–2.0) 1.0 (1.0–2.0)
Cmax, mean (SD), mg/mL 1.33 (0.460) 3.07 (0.810) 4.95 (0.947) 8.17 (2.16) 11.5 (2.02)
Cmax per dose, mg/mL/mg 0.0133 0.0154 0.0123 0.0102 0.0096
Cmin (mg/mL) 0.0105
(0.0105)
0.0395
(0.0141)
0.0523
(0.0188)
0.0963
(0.0301)
0.179
(0.0634)
AUC0–t, mean (SD), h  mg/mL 4.46 (0.882) 11.5 (1.85) 17.8 (3.40) 31.4 (8.58) 54.3 (0.804)
AUC0–t per dose, h  mg/mL/mg 0.0446 0.0575 0.0445 0.0393 0.0453
t½, harmonic mean, h 4.2 7.4 8.4 8.5 7.6
CL/F, mean (SD), L/h 23.1 (4.1) 17.7 (2.6) 23.3 (4.8) 27.1 (7.2) 22.5 (3.6)
Vz/F, mean (SD), L 154.1 (60.6) 235.9 (142.2) 347.0 (222.5) 386.6 (197.5) 315.1 (186.4)
AR,* mean (SD) 1.10 (0.07) 1.03 (0.12) 1.24 (0.33) 1.15 (0.13) 1.18 (0.10)
fe, mean (SD) 29.3 (13.5) 29.4 (11.3) 23.9 (14.4) 18.9 (25.9) 23.9 (9.3)
CLr, mean (SD), L/h 5.9 (3.2) 5.9 (2.3) 6.2 (4.0) 7.1 (8.1) 4.2 (2.0)
AR ¼ accumulation ratio; CLr ¼ renal clearance of delaﬂoxacin; fe ¼ fraction of dose recovered as unchanged delaﬂoxacin in
urine; Vz/F ¼ volume of distribution in the terminal phase.
*Day 5 AUC0–24/day 1 AUC0–24.
Clinical Therapeuticsgiven delaﬂoxacin (900 mg) under fasted conditions
with a meal 2 hours after dosing, 6 participants
(20.7%) after delaﬂoxacin (900 mg) under fed
conditions, and 4 (14.3%) after delaﬂoxacin (900
mg) under fasted conditions. The most frequently
reported TEAE was diarrhea (5 participants
[16.7%]).DISCUSSION
Delaﬂoxacin is an investigational ﬂuoroquinolone that
is currently in Phase III development as an intravenous
and oral product for the treatment of ABSSSIs. In 248Phase II studies, delaﬂoxacin given as an intravenous
infusion provided comparable outcomes to approved
comparators in the treatment of complicated skin and
skin structures infections and ABSSSIs.8,9 In these 2
studies, delaﬂoxacin was well tolerated, with the most
common AEs reported being nausea, vomiting, and
diarrhea. The oral formulation of delaﬂoxacin allows
for convenience and ﬂexibility for the treatment of
patients with skin infections.
The present report describes the ﬁrst-in-human
single and multiple ascending-dose trial of oral
delaﬂoxacin conducted in healthy volunteers. In this
study, delaﬂoxacin was administered as unformulatedVolume 38 Number 1
Table IV. Effect of sex and age on the pharmacokinetic parameters of delafloxacin after a single oral 250-mg
dose (neat chemical in capsule).
Pharmacokinetic Parameter
Young Men
(n ¼ 16)
Young Women
(n ¼ 12)
Elderly Men
(n ¼ 6)
Elderly Women
(n ¼ 6)
Tmax, median (range), h
§ 1.0 (0.5–4.0) 1.0 (1.0–4.0) 1.0 (1.0–2.0) 1.0 (1.0–1.5)
Cmax, mean (SD), mg/mL 3.58 (0.602)
* 3.89 (1.27)* 4.62 (0.793) 5.30 (1.06)
AUC0–1, mean (SD), h  mg/mL 13.6 (2.85)* 14.4 (2.63)* 19.3 (4.84) 19.0 (3.55)
t½, harmonic mean, h
† 8.3 9.0 5.9 7.1
CL/F, mean (SD), L/h‡ 19.3 (4.8) 17.8 (2.6) 13.7 (3.4) 13.6 (2.5)
Vz/F, mean (SD), L
‡ 444 (605) 551 (731) 158 (147) 164.6 (84.7)
Vz/F ¼ volume of distribution in the terminal phase.
*Statistically signiﬁcantly different from elderly individuals (ANOVA, P o 0.05).
†Evaluations of t½ were based on statistical tests for ke.
‡Parameter was not tested statistically.
§Median (minimum, maximum).
R. Hoover et al.drug in a gelatin capsule under fasting conditions.
The doses given covered a wide dose range after both
single and repeated administration. Delaﬂoxacin wasCmax
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Figure 3. Association between baseline creati-
nine clearance (CLcr) and AUC0–1 or
Cmax values for young and elderly men
and women.
January 2016well tolerated, with the most common TEAE reported
being gastrointestinal events (nausea, vomiting, and
diarrhea). Delaﬂoxacin at doses of Z800 mg had the
highest incidences of diarrhea. Some participants had
ALT values above the normal range, but an associ-
ation with study drug could not be established because
there was no clear dose response and most of the
elevations occurred 4 days after the end of dosing and
conﬁnement. Studies with larger numbers of patients
and of longer duration are needed to fully assess the
potential effects of delaﬂoxacin on ALT. In Phase II
studies of delaﬂoxacin in patients with complicated skin
and skin-structure infections and ABSSSIs, no clinically
relevant treatment-related ALT elevations were ob-
served.8,9 No evidence of QTc prolongation was ob-
served, which is consistent with results from a thorough
QTc study.14 Age, sex, or the administration of
drug with food did not change the safety proﬁle of
delaﬂoxacin.
Delaﬂoxacin was rapidly absorbed after oral ad-
ministration with peak concentrations occurring ap-
proximately 1 hour after dosing. At doses Z200 mg,
delaﬂoxacin concentrations decreased in plasma in a
biexponential manner with a terminal half-life of
approximately 6 to 8 hours. At doses o200 mg of
plasma, delaﬂoxacin decreased in a monoexponential
manner with a short half-life (approximately 2 hours)
likely due to the sensitivity limits of the assay
preventing detection of the terminal elimination phase.49
Table V. Pharmacokinetic parameters of delafloxacin after a single oral 900-mg dose (2  450-mg tablet):
effect of food.
Parameter
Delaﬂoxacin (900 mg, 2  450-mg Tablet)
Fasted (n ¼ 28) Fed (n ¼ 20)
Fasted, With Meal 2 Hours
After Dosing (n ¼ 25)
Tmax, median (range) 1.25 (0.50–4.00) 2.50 (1.00–6.00) 1.50 (0.50–2.50)
*
Cmax, mean (SD), mg/mL 11.5 (2.76) 9.14 (2.81) 11.8 (2.64)
*
AUC0–t, mean (SD), h  mg/mL 56.2 (15.21) 57.1 (14.15) 49.8 (12.01)
AUC0–1, mean (SD), h  mg/mL 55.2 (13.68) 58.2 (11.41) 52.2 (12.55)†
*n ¼ 23.
†n ¼ 9, 16, and 14 for fasted, fed, and fasted with a meal 2 hours after dosing, respectively.
Clinical TherapeuticsThe half-life of delaﬂoxacin was longer after multiple
doses compared with single-dose administration. This
observation may be a result of data up to 48 hours
being available for the day 5 estimation, whereas data
only up to 24 hours were available for the day 1
estimation. Secondary peak plasma concentrations
were observed in several participants, which may be
due to enterohepatic cycling, also making it difﬁcult to
provide an accurate estimate of elimination half-life.Table VI. Effect of food on the pharmacokinetic parame
Parameter Treatment* N
Geome
Cmax, mean (SD), mg/mL A 28 10.
B 29 8.2
C 23 10.
AUC0–t, mean (SD), h  mg/mL A 28 51.
B 29 52.
C 25 45.
AUC0–1, mean (SD), h  mg/mL A 9 49.
B 16 52.
C 14 49.
LS ¼ least squares.
*Treatment A was 900 mg oral delaﬂoxacin (2  450-mg fo
delaﬂoxacin (2  450-mg formulated tablets), fed; and treatme
tablets), fasted, with a meal 2 hours after dosing.
50In a human intravenous radiolabeled delaﬂoxacin
mass balance study, approximately 28% of the ad-
ministered radioactivity was excreted as unchanged
delaﬂoxacin in feces, which likely arose from biliary
excretion and/or transintestinal elimination, suggest-
ing the possibility of enterohepatic cycling.15 On
multiple daily dosing, a steady state in delaﬂoxacin
plasma concentrations was reached in approximately
3 days with minimal accumulation (25%). The Cmaxters of oral delafloxacin (tablet formulation).
tric LS Estimate
(90% CI)
Treatment
Comparison
Geometric LS Mean
Ratio, % (90% CI)
3 (9.41–11.3)
0 (7.50–8.96) B/A 79.5 (73.1–86.4)
5 (9.56–11.6) C/A 102 (93.6–112)
4 (47.1–56.2)
3 (48.0–57.1) B/A 102 (95.7–108)
9 (41.9–50.3) C/A 89.3 (83.8–95.1)
5 (43.7–56.0)
0 (47.1–57.3) B/A 105 (92.1–120)
6 (44.6–55.2) C/A 100 (86.7–116)
rmulated tablets), fasted; treatment B was 900 mg oral
nt C was 900 mg oral delaﬂoxacin (2  450-mg formulated
Volume 38 Number 1
R. Hoover et al.of delaﬂoxacin generally increased with increasing
dose, and the AUC increased proportionally with
dose at doses Z200 mg.
There were no observed sex differences in delaﬂoxacin
pharmacokinetic parameters in the young and elderly
populations. Systemic exposure to delaﬂoxacin was
higher in elderly individuals compared with young adults,
which could be attributed in part to lower creatinine
clearance in the elderly individuals. The correlation of
delaﬂoxacin exposure to creatinine clearance is expected
because unchanged delaﬂoxacin is partially eliminated by
renal ﬁltration. After intravenous administration of radio-
labeled delaﬂoxacin, approximately 66% of the dose is
excreted in urine, most of which is unchanged delaﬂox-
acin.15 Delaﬂoxacin clearance is also reduced in patients
with moderate and severe renal impairment.16
The administration of ciproﬂoxacin with food
results in delayed absorption.17 The absorption of
ﬂuoroquinolones, ciproﬂoxacin, and norﬂoxacin
decreases when coadministered with milk or milk
products.18,19 The effect of coadministration with a
high-fat meal, including milk, on the pharmacokinetic
parameters of delaﬂoxacin was examined after admin-
istration of delaﬂoxacin as an unformulated chemical
in a gelatin capsule (250 mg) and in the tablet
formulation (900 mg given as 2  450-mg tablets).
Delaﬂoxacin Tmax was prolonged when given with
food regardless of formulation, most likely due to a
delay in stomach emptying. When given as unformu-
lated chemical, Cmax was reduced signiﬁcantly (50%),
but total exposure was minimally decreased. When
delaﬂoxacin was administered in a formulated tablet
with food, Cmax was reduced slightly (20%), but again
total exposure (AUC) was not signiﬁcantly changed.
Consumption of a meal 2 hours after the administra-
tion of delaﬂoxacin did not have a signiﬁcant effect on
its absorption. The food effect on Cmax is not
considered clinically relevant because efﬁcacy for
delaﬂoxacin, as with other ﬂuoroquinolones, is likely
more dependent on total and not peak exposure.20,21
These results indicate that delaﬂoxacin can be given
without regard to food when administered in the
current formulated tablet.CONCLUSIONS
In summary, delaﬂoxacin was generally well tolerated
when given orally to healthy volunteers over a wide
dose range, with gastrointestinal AEs more commonlyJanuary 2016observed with single doses of 41200 mg and with
multiple doses of Z800 mg. Delaﬂoxacin was well
absorbed with pharmacokinetic characteristics that
are supportive of twice-daily dosing that is currently
being evaluated in Phase III studies of ABSSSIs.ACKNOWLEDGMENTS
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